Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Decreased pulmonary exacerbations and lower intravenous antibiotic usage following vanzacaftor/tezacaftor/deutivacaftor treatment in people with cystic fibrosis with F508del-minimal function genotypes.
Journal: The European respiratory journal
Published: November 25, 2025
Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.
Journal: Annals of the American Thoracic Society
Published: October 03, 2025
Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Journal: The Lancet. Respiratory medicine
Published: October 25, 2024
Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: October 17, 2024
Sweat chloride reflects CFTR function and correlates with clinical outcomes following CFTR modulator treatment.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: August 11, 2024
Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis.
Journal: Journal of patient-reported outcomes
Published: June 15, 2023
Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Journal: The Lancet. Respiratory medicine
Published: September 29, 2022
Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-Revised.
Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Published: December 15, 2021
Transparency and diversity in cystic fibrosis research - Authors' reply.
Journal: Lancet (London, England)
Published: March 12, 2020
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Journal: Lancet (London, England)
Published: August 24, 2019
Correlating Cystic Fibrosis Transmembrane Conductance Regulator Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis.
Journal: American journal of respiratory and critical care medicine
Published: March 20, 2019
Decreased mRNA and protein stability of W1282X limits response to modulator therapy.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: November 21, 2018
Last Updated: 09/26/2026